Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Regulation of Stroke Volume01:27

Regulation of Stroke Volume

4.6K
The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
4.6K
Imaging Studies VII: Vascular Imaging01:19

Imaging Studies VII: Vascular Imaging

297
DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...
297
Imaging Studies for Cardiovascular System II:Types of Echocardiography01:20

Imaging Studies for Cardiovascular System II:Types of Echocardiography

612
Echocardiography plays a role in assessing cardiac health and detecting heart conditions, with various types providing critical insights for diagnosis and treatment.
Types of Echocardiography
Transthoracic Echocardiography (TTE)
TTE is the most common type of echocardiogram which involves placing a transducer on the patient's chest, emitting sound waves to create heart images. TTE is invaluable for evaluating the heart's size, structure, and motion, making it particularly useful for...
612
Imaging Studies for Cardiovascular System III: X-Ray01:20

Imaging Studies for Cardiovascular System III: X-Ray

457
The most common cardiovascular diagnostic test is an X-ray. It produces images of the heart, blood vessels, and adjacent structures.
Definition and Purpose
An X-ray, or radiograph, is a non-invasive method that uses ionizing radiation to take images of internal structures. It is mainly used in cardiac imaging to examine the heart, lungs, and major blood vessels, aiming to identify abnormalities in the heart's size, shape, and position, such as heart failure, congenital defects, and vascular...
457

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plaque Volume Rather than Echogenicity for Identification of Active Carotid Plaques.

Angiology·2026
Same author

From Narrowing to Vulnerability: Rethinking Carotid Revascularization in the Era of Advanced Imaging.

European journal of preventive cardiology·2026
Same author

Albuminuria and Carotid Atherosclerosis in Type 1 Diabetes Evaluated Using Three-Dimensional Vascular Ultrasound.

Diabetes, obesity & metabolism·2026
Same author

The prevalence of carotid subclinical atherosclerosis according to age: A systematic review and meta-analysis of the young to middle-age.

Journal of clinical lipidology·2025
Same author

"The medicine doesn't interest me at all." Beliefs, health behaviors, and medication adherence in peripheral arterial disease.

VASA. Zeitschrift fur Gefasskrankheiten·2025
Same author

Pre-admission Opioid Use and Associated Outcomes in Patients Revascularised for Lower Peripheral Artery Disease.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2025

Related Experiment Video

Updated: Jan 12, 2026

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics
08:42

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

9.2K

Rivaroxaban Does Not Alter Carotid Plaque Echolucency, Volume, or Neovascularisation.

Majken Lyhne Jessen1, Karin1, Antoine Collet-Billon2

  • 1Department of Vascular Surgery, Heart Centre, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery
|November 8, 2025
PubMed
Summary

Rivaroxaban did not change carotid plaque echolucency, volume, or neovascularisation in patients with peripheral arterial disease. This study found no significant differences between rivaroxaban and placebo groups over 12 months.

Keywords:
Atherosclerosis, Carotid artery disease, Contrast enhanced ultrasound, Rivaroxaban, Three-dimensional ultrasound

More Related Videos

A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis
09:36

A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis

Published on: August 12, 2025

531
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.8K

Related Experiment Videos

Last Updated: Jan 12, 2026

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics
08:42

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

9.2K
A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis
09:36

A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis

Published on: August 12, 2025

531
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.8K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Medical Imaging

Background:

  • Atherosclerotic carotid plaques are a significant risk factor for stroke.
  • Echolucency, volume, and neovascularization are key indicators of plaque instability.
  • Rivaroxaban is an anticoagulant with potential anti-inflammatory effects.

Purpose of the Study:

  • To investigate the impact of rivaroxaban on carotid plaque characteristics.
  • To compare the effects of rivaroxaban versus placebo on plaque echolucency, volume, and neovascularization.
  • To assess the safety and efficacy of rivaroxaban in patients with peripheral arterial disease and carotid atherosclerosis.

Main Methods:

  • A double-blind, randomized, placebo-controlled trial involving patients with peripheral arterial disease and asymptomatic carotid disease.
  • Patients received either rivaroxaban (2.5 mg twice daily) or placebo, in addition to aspirin and statins.
  • Carotid plaque characteristics, including echolucency (grayscale median), volume, and intraplaque neovascularization (IPN), were assessed using advanced ultrasound techniques over a 12-month period.

Main Results:

  • No significant differences were observed in plaque echolucency (grayscale median) between the rivaroxaban and placebo groups.
  • Changes in plaque volume and intraplaque neovascularization scores over time were similar in both treatment arms.
  • The study included 28 patients in the rivaroxaban group and 29 in the placebo group for final analysis.

Conclusions:

  • Rivaroxaban treatment did not significantly alter carotid plaque echolucency, volume, or intraplaque neovascularization in patients with peripheral arterial disease.
  • The findings suggest that rivaroxaban, at the studied dosage, does not impact the progression of atherosclerotic carotid plaques in this patient population.
  • Further research may be warranted to explore other therapeutic strategies for managing carotid plaque instability.